When it comes to drug manufacturers erecting barriers around 340B contract pharmacies, we’ve gone past the “kick ‘em while they’re down” phase and into a straight-up pile-on.
With the recent news about AbbVie, Bristol Myers Squibb and now Pfizer, there are now a baker’s dozen (13) drug manufacturers that have placed restrictions on accessing 340B drugs at contract pharmacies. (By the time you read this, there could well be more, such is the nature of this seemingly runaway train.) And with big-name pharmaceutical companies like Eli Lilly, Sanofi and AstraZeneca among the ranks, chances are the exclusions are taking a bite out of your 340B program benefits.
The question we increasingly hear from our customers is, what should we do now?
Mark your calendars
We’ll explore that question in depth and provide other updates in an upcoming webinar, “Keeping Up with the Manufacturer Mayhem,” at 2 p.m. ET Wednesday, Feb. 16. Registration is now open for our covered entities and contract pharmacy partners by contacting your Sentry account manager.
In some cases, covered entities can pick at least one contract pharmacy where the manufacturers say they will honor 340B ceiling prices without sharing data. However, the latest trend is to permit 340B contract pharmacy pricing only if CEs agree to share claims data so the manufacturers can verify that they aren’t providing duplicate discounts. Covered entities are understandably curious as to whether using a third-party platform to share their data is the right path. Some have already decided to play along.
Come learn about data submission as an option and what alternatives exist for you to leverage. Bring your legal counsel, your compliance team and your core 340B team to learn and understand how we can leverage our combined resources so you can make the best decision for your unique circumstances.
Support from the onset
Sentry is committed to helping our customers by compiling impact reports that detail the lost savings from each manufacturer. It’s something we’ve been doing since Eli Lilly made the first announcement to restrict 340B contract pharmacy pricing in 2020. It’s a significant differentiator, as not every 340B vendor can claim such a capability. Sentry also continues talking with all stakeholders, including the drug manufacturers and 340B ESP, one of the third-party data-sharing platforms, to understand their processes and how we can best help support our customers. We also will discuss your options should you choose to submit data and how we are supporting customers that choose that route using our robust reporting.
We understand these are challenging circumstances and that many options have their own drawbacks. Our goal in the webinar is to outline the options and their ramifications, and to hear from you, our customers. What are you doing to counter the pressure? How are you offsetting the contract pharmacy losses? What’s been your experience providing claims data to 340B ESP?
We look forward to hearing from you on Feb. 16. Register by contacting your account manager.